（文章来源：证券日报） 证券日报网讯 9月1日晚间，海正药业发布公告称，2025年8月，公司未回购股份。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/5/13 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 5 月 5 | 12 | 日~2026 | 年 | 月 | 11 | 日 | | 预计回购金额 | 5,000万元~10,000万元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 5,535,000股 | | | | | | | | 累计已回购股数占总股本比例 | 0.46% | | | | | | | | 累计已回购金额 | 50,891,385.00元 | | | | | | | | 实际回购价格区间 | 8.92元/股~9.40元/股 | | | | | | | 一 ...

每经头条（nbdtoutiao）——个人消费贷贴息明日开闸！贷30万元最多可享贴息3000元，一文读懂→ （记者 张喜威） 截至发稿，海正药业市值为131亿元。 每经AI快讯，海正药业（SH 600267，收盘价：10.92元）9月1日晚间发布公告称，截至2025年8月月 底，公司已累计回购股份约554万股，占公司总股本的比例为0.46%，购买的最高价为9.4元/股、最低价 为8.92元/股，已支付的总金额约为5089万元。 2024年1至12月份，海正药业的营业收入构成为：医药生产占比58.46%，药品销售占比39.29%，其他行 业占比1.94%，其他业务占比0.23%，CMO/CDMO/CRO业务占比0.08%。 ...

格隆汇9月1日丨海正药业(600267.SH)公布，截至2025年8月月底，公司已累计回购股份553.5万股，占公 司总股本的比例为0.46%，购买的最高价为9.40元/股、最低价为8.92元/股，已支付的总金额为5089.14万 元（不含交易费用）。 ...

Core Insights - Heilongjiang Province is positioned as a strategic hub in the "Belt and Road" initiative, particularly in the China-Mongolia-Russia Economic Corridor, with significant potential for cooperation in the new materials industry and technology [1][2] - The province has a strong resource endowment, industrial foundation, educational resources, geographical advantages, and diverse application scenarios for developing the new materials industry [1][2] Industry Development - The province has discovered 149 types of mineral resources, with crystalline graphite reserves of 379 million tons, accounting for over 53.7% of the national total, ranking first in the country [1] - Molybdenum reserves are 2.687 million tons, placing Heilongjiang fifth nationally [1] Investment Promotion - The investment promotion event aimed to showcase the advantages of Heilongjiang's new materials industry, investment projects, and business environment, facilitating collaboration among innovation, industry, capital, and talent chains [1][2] - Various enterprises, including China Nonferrous Mining Group and others, shared their investment experiences and future plans in Heilongjiang, providing targeted suggestions for the development of the new materials industry [2] Policy and Collaboration - Heilongjiang is mobilizing resources from government, industry, academia, and research to enhance the quality and scale of its industries, achieving solid results in innovation, scale, transformation, and cluster development [2]

Core Insights - The pharmaceutical industry in the first half of 2025 is characterized by deepening centralized procurement and intense market competition, with companies balancing between stabilizing their fundamentals and seeking growth [2] - Haizheng Pharmaceutical (600267.SH) reported a mid-year performance that stands out, achieving slight revenue growth despite industry pressures, while net profit declined [2][3] - The company plans to divest Zhejiang Pharmaceutical Industry Co., aiming to lighten its operational burden for future development [2][7] Financial Performance - In the first half of 2025, Haizheng Pharmaceutical achieved revenue of 5.25 billion yuan, a slight increase of 0.13% year-on-year, maintaining a stable business foundation amid industry challenges [3] - Net profit decreased by 31.29% year-on-year, influenced by reduced convertible bond repurchase income; however, the adjusted net profit excluding non-recurring items grew by 23.92% to 321 million yuan [3] - The gross profit margin improved to 43.94%, driven by product structure optimization and cost management [4] Business Segments - The core pharmaceutical manufacturing segment remains a key revenue driver, with steady sales growth from major products like "Saismei" and "Meiman" [3] - The pet health sector emerged as a new growth area, with over 60% year-on-year growth in pet business, and the e-commerce segment surpassing 100 million yuan in sales [3] Strategic Initiatives - The company is focusing on long-term competitiveness through R&D innovation and emerging business layouts, including the development of a first-class innovative drug HS387 for oncology [6] - Haizheng Pharmaceutical is pursuing a "self-research + collaboration" model, with significant investments in synthetic biology and AI drug development [6] - The divestiture of Zhejiang Pharmaceutical Industry Co. is part of a strategy to concentrate resources on high-value areas, despite potential short-term revenue impacts [7]

Core Viewpoint - The company focuses on two main business segments: pharmaceutical equipment and energy-saving environmental protection equipment, aiming for synergistic development [1][2]. Business Structure - The pharmaceutical equipment segment is primarily managed by the company, with key products including vial cleaning machines and filtration washing and drying machines, serving major domestic API producers and expanding into overseas markets like India and the Middle East [1]. - The wholly-owned subsidiary, Leheng Energy, specializes in environmental protection equipment, with core products such as steam compressors and MVR systems, catering to sectors like new energy and fine chemicals, and has established overseas markets through collaboration with Albemarle [1]. Research and Innovation - The company invested 15.94 million yuan in R&D in the first half of the year, a decrease of 28.03% year-on-year, but focused resources on high-end pharmaceutical equipment and MVR system optimization [1]. - Both the company and Leheng Energy are recognized as high-tech enterprises, with multiple invention patents and over a hundred utility model patents, showcasing strong technical capabilities [1]. Market Outlook - For the second half of the year, the company plans to accelerate the expansion of its pharmaceutical equipment in overseas markets and deepen the application of MVR systems in the new energy sector [2]. - Market analysis suggests that the company is well-positioned to strengthen its industry position and achieve steady growth due to the release of equipment upgrade demands in the pharmaceutical industry and the increasing need for energy-saving environmental protection equipment under carbon reduction goals [2]. Financial Performance - In the first half of the year, the company reported revenue of 345 million yuan, a year-on-year increase of 15.08%, and a net profit attributable to shareholders of 41.29 million yuan [3]. - The net cash flow from operating activities saw a significant increase of 106.93% year-on-year, indicating strong operational resilience [3].

Industry Overview - The pet medical market is transitioning from a niche sector to a competitive arena, driven by the increasing demand for pet healthcare as pets are considered family members [1][2] - The pet medical market is projected to account for approximately 28% of total pet consumption in urban China by 2024, with a market size of around 800 billion yuan [2] Company Involvement - Numerous listed companies and large pharmaceutical firms are entering the pet medicine sector, including Hai Zheng Pharmaceutical, Huadong Medicine, and Reap Bio [2][3] - Hai Zheng Dongbao, a subsidiary of Hai Zheng Pharmaceutical, has become a leading brand in the domestic pet medicine market, focusing on deworming drugs and vaccines [3] Market Potential - The pet medicine market is primarily composed of deworming drugs, skin disease medications, and vaccines, with deworming drugs accounting for about 60% of the market share [4] - There is a significant demand for medications targeting elderly pets, chronic diseases, and tumors, indicating a potential growth area for the pet medicine industry [5][6] R&D and Innovation - The R&D costs for pet medicines are significantly lower than for human medicines, with pet innovation drugs typically costing between 20 million to 30 million yuan [2][5] - Hai Zheng Dongbao plans to leverage its human medicine resources to enhance its pet medicine R&D capabilities, aiming to reduce costs and risks [3][6] Vaccine Development - The domestic pet vaccine market is experiencing accelerated progress in local alternatives, with the first domestically approved cat trivalent vaccine set to launch in January 2024 [7] - By mid-2025, 11 domestic cat trivalent vaccines are expected to be available, with domestic vaccines capturing a 25% market share [7][8] Future Outlook - The aging pet population is anticipated to drive the demand for pet healthcare services, with over 30 million pets expected to enter middle age in the next three years [5] - Companies are focusing on developing a product matrix that includes both vaccines and chemical drugs to meet the growing market needs [8]

Core Viewpoint - Haizheng Pharmaceutical reported steady growth in its business performance for the first half of 2025, focusing on business growth and efficiency improvement, achieving operating revenue of 5.25 billion yuan and a net profit attributable to shareholders of 299 million yuan, with a 23.92% year-on-year increase in net profit after deducting non-recurring gains and losses [1] Financial Performance - The company generated a net cash flow from operating activities of 1.211 billion yuan, representing a year-on-year increase of 54.98% [1] - The net profit after deducting non-recurring gains and losses reached 321 million yuan [1] Business Segments - The formulation sales business maintained steady growth, with products such as Saismei, Ximeixin, and Niuzaili showing sales revenue increases of over 30% [2] - Saismei, as the first domestically developed innovative drug in the cholesterol absorption inhibitor category, is highly recommended in national guidelines [2] - The company is focusing on chronic disease management, particularly in cardiovascular and metabolic diseases, and has initiated several health promotion projects [2] Product Development - Haizheng Pharmaceutical continues to deepen its presence in various disease areas, with Ximeixin leading in the market for cholestatic liver disease treatments and Niuzaili becoming a new standard for community-acquired infections [3] - The pet medicine sector showed strong growth, with overall sales increasing by over 60%, and the pet e-commerce business achieving sales exceeding 100 million yuan [3] - The company launched several new products in the pet healthcare market, including a new antibiotic for dogs and cats and a vaccine for cats [3] Strategic Initiatives - The establishment of a joint venture focused on synthetic biology marks a significant step into the high-end synthetic biology industry [4] - The company is enhancing internal operational efficiency through refined management of sales expenses and continuous technological innovation in production [4] - Looking ahead, Haizheng Pharmaceutical aims to leverage cutting-edge technologies such as synthetic biology and AI in drug development to enhance long-term value creation [4]

Core Insights - The pet medicine market in China is entering a transformative phase driven by the growing pet ownership and the increasing awareness of scientific pet care [2][3] - The domestic pet medicine market is expected to see the pet business segment exceed 50% by 2025, indicating a shift from traditional livestock to pet-focused products [3] Market Competition - The current pet medicine market is characterized by intense competition and fragmentation, with many companies vying for market share [4] - Price wars have emerged due to an influx of products, leading to significant market value compression, with some products priced as low as 9.9 yuan [4] - Companies must adapt to a variety of sales channels, including online platforms and physical stores, to survive in this competitive landscape [4] Innovation Strategy - Chinese pet medicine companies have closed the technological gap with international giants, with a focus on practical innovation rather than chasing new technology for its own sake [5][6] - The market for innovative pet medicines is expected to grow, with a focus on high-demand areas such as parasitic treatments and skin diseases [6] - The willingness of pet owners to spend on common medications like vaccines is significantly higher compared to niche treatments, influencing product development strategies [5] International Expansion - The domestic pet medicine market lacks a "blue ocean" strategy, prompting companies to look for growth opportunities abroad [7] - Companies face challenges in international markets due to reliance on product agents and the need for brand establishment rather than just product export [7] - The company has a competitive advantage due to its established global trade network, facilitating entry into Southeast Asian markets [7][8] Regulatory Challenges - Entering new markets requires significant investment in meeting local regulatory standards, which can be resource-intensive and time-consuming [8] - To penetrate the European and American markets, companies must comply with stringent standards and certifications, necessitating the establishment of independent production lines [8][9]